Posts by: Janet Stewart, MSc

Janet Stewart, MSc

Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.

April 11, 2018April 11, 2018

First Patient Treated in Test of OLT38, a Dye to Detect Ovarian Cancer Tissue During Surgery

News

A Phase 3 clinical trial testing a special dye that “lights up” ovarian tumor tissue during surgery has treated its first participant, On Target Laboratories announced. The dye, called OTL38, is ... Read more

March 14, 2018March 14, 2018

BARD1 Test Detected Ovarian Cancer in 82% of Patients with the Disease, Study Shows

News

A new BARD1 Life Sciences test was able to detect ovarian cancer in 82% of those with the disease, the company announced. The 400 cases in the BARD1-Ovarian test study covered all stages and ... Read more

January 12, 2018

Immix to Initiate Phase 1/2a Trial of IMX-110 in Ovarian, Other Solid Tumors

News

A Phase 1/2a trial of Immix Biopharma’s IMX-110, a combination treatment targeting advanced solid tumors, including ovarian cancer, has received the necessary ethics board approval to begin. The trial (NCT03382340) ... Read more

December 18, 2017December 18, 2017

Masitinib Counteracts Resistance to Ovarian Cancer Therapy in Cell Cultures

News

Researchers discovered how AB Science’s therapy masitinib — a veterinary medicine sold as Kinavet in the U.S. — acts to re-sensitize drug-resistant tumor cells to the anti-cancer treatment Gemzar (gemcitabine). ... Read more

December 1, 2017December 1, 2017

European Commission Approves Tesaro’s Zejula as Maintenance Therapy for Ovarian Cancer

News

The European Commission has approved Tesaro‘s Zejula (niraparib) as a maintenance treatment for ovarian cancer, with or without BCRA mutations, in women who have shown a complete or partial response ... Read more

November 3, 2017

FDA OKs Mersana’s XMT-1536 for Clinical Investigation in Ovarian, Other Solid Tumors

News

Mersana Therapeutics is advancing its antibody-drug conjugate XMT-1536 into clinical development for ovarian and other tumor types, after the U.S. Food and Drug Administration cleared the company’s investigational new drug (IND) ... Read more

October 27, 2017

FDA to Review Genentech’s Avastin as Front-line Treatment for Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration has accepted for review Genentech‘s supplemental Biologics License Application (sBLA) seeking the approval of Avastin (bevacizumab) in combination with chemotherapy, as a front-line treatment for ... Read more

October 25, 2017

ICER Report Concludes Comparative Value of PARP Inhibitors is Lacking

News

The Institute for Clinical and Economic Review (ICER), an independent body that assesses the value of drugs newly approved by the U.S. Food and Drug Administration, confirmed that evidence is ... Read more

October 9, 2017October 9, 2017

After Disappointing Results, Mateon to End FOCUS Trial for CA4P in Ovarian Cancer Patients

News

Mateon Therapeutics announced that it is immediately ending the FOCUS trial of CA4P to treat platinum-resistant ovarian cancer, based on disappointing interim results. The results showed that CA4P (fosbretabulin) did not significantly ... Read more

September 27, 2017September 27, 2017

Chemotherapy Every 3 Weeks Seen as Effective as Weekly Dosing in European Ovarian Cancer Patients

News

Researchers compared weekly doses of Taxol (paclitaxel) to treat ovarian cancer with dosing every three weeks in a European trial to determine if weekly dosing was more effective. They found that ... Read more